A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business Overview We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio worldwide, which is currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe, United Kingdom (UK), Canada and Israel. Peer-reviewed publication of positive data from its pivotal clinical trial of FemaSeed demonstrated effectiveness and safety with high satisfaction from both patients and practitioners. FemVue®, a companion diagnostic for fallopian tube assessment via ultrasound, is U.S.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 2.1M | - | - | - | - | 1.0M |
| Net Income | -20M | -19M | -14M | -11M | -7.5M | - |
| EPS | $-0.69 | $-0.85 | $-0.93 | $-0.96 | $-1.12 | $-7.20 |
| Free Cash Flow | -20M | -20M | -11M | -11M | -8.2M | -4.9M |
| ROIC | -85.8% | -151.0% | -63.0% | -54.8% | -29.2% | - |
| Gross Margin | 63.1% | - | - | - | - | 70.5% |
| Debt/Equity | 0.12 | 5.58 | 0.37 | 0.06 | 0.04 | -0.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -18M | -18M | -15M | -12M | -8.3M | -6.9M |
| Operating Margin | -858.0% | - | - | - | - | -668.0% |
| ROE | -434.6% | -182.2% | -77.6% | -54.8% | -28.6% | - |
| Shares Outstanding | 58M | 22M | 15M | 12M | 7M | 1M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.0M | N/A | N/A | N/A | N/A | 2.1M |
| Gross Margin | 70.5% | N/A | N/A | N/A | N/A | 63.1% |
| R&D | 4.1M | 4.1M | 5.8M | 7.2M | 8.2M | 7.9M |
| SG&A | 2.5M | 4.3M | 5.4M | 6.9M | 6.3M | 6.5M |
| EBIT | -6.9M | -8.3M | -12M | -15M | -18M | -18M |
| Op. Margin | -668.0% | N/A | N/A | N/A | N/A | -858.0% |
| Net Income | N/A | -7.5M | -11M | -14M | -19M | -20M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -960.5% |
| Non-Recurring | 0 | -3K | -2K | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/A | -29.2% | -54.8% | -63.0% | -151.0% | -85.8% |
| ROE | N/A | -28.6% | -54.8% | -77.6% | -182.2% | -434.6% |
| ROA | N/A | -41.7% | -50.1% | -51.3% | -93.6% | -121.6% |
| Cash Flow | ||||||
| Op. Cash Flow | -4.9M | -7.9M | -11M | -11M | -19M | -20M |
| Free Cash Flow | -4.9M | -8.2M | -11M | -11M | -20M | -20M |
| Owner Earnings | -7.4M | -11M | -14M | -12M | -20M | -21M |
| CapEx | 8K | 307K | 407K | 144K | 762K | 492K |
| Maint. CapEx | 2.2M | 2.7M | 3.2M | 483K | 297K | 302K |
| Growth CapEx | 0 | 0 | 0 | 0 | 464K | 190K |
| D&A | 2.2M | 2.7M | 3.2M | 483K | 297K | 302K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 230K | 61K | 61K |
| Buyback Yield | N/A | N/A | N/A | 1.5% | 0.2% | 0.2% |
| Stock-Based Comp | 319K | 193K | 225K | 676K | 444K | 858K |
| Debt Repayment | 0 | 0 | 0 | 525K | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -2.3M | -24M | -12M | -37M | 5.9M | -8.6M |
| Cash & Equiv. | 3.3M | 25M | 13M | 22M | 3.5M | 9.1M |
| Long-Term Debt | 39K | 16K | 0 | 4.3M | 0 | N/A |
| Debt/Equity | -0.04 | 0.04 | 0.06 | 0.37 | 5.58 | 0.12 |
| Interest Coverage | -552.3 | -433.6 | -861.6 | -87.7 | -11.1 | -11.1 |
| Equity | -52M | 26M | 15M | 18M | 2.3M | 4.6M |
| Total Assets | 7.6M | 29M | 17M | 28M | 12M | 16M |
| Total Liabilities | 4.1M | 2.2M | 1.7M | 9.4M | 10M | 12M |
| Intangibles | 65K | 25K | 3K | 0 | 66K | 130K |
| Retained Earnings | -75M | -83M | -94M | -108M | -127M | -142M |
| Working Capital | 975K | 24M | 13M | 20M | -560K | 1.7M |
| Current Assets | 3.9M | 26M | 14M | 23M | 8.0M | 12M |
| Current Liabilities | 2.9M | 1.7M | 1.5M | 3.1M | 8.6M | 11M |
| Per Share Data | ||||||
| EPS | -7.20 | -1.12 | -0.96 | -0.93 | -0.85 | -0.69 |
| Owner EPS | -7.50 | -1.61 | -1.19 | -0.81 | -0.91 | -0.35 |
| Book Value | -52.17 | 3.91 | 1.28 | 1.20 | 0.10 | 0.08 |
| Cash Flow/Share | -4.97 | -1.18 | -0.90 | -0.74 | -0.88 | -0.33 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.0M | 6.7M | 11.9M | 15.3M | 22.1M | 58.5M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -0.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.9 | 0.7 | 0.8 | 10.9 | 5.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 12.2 |
| FCF Yield | N/A | -34.8% | -106.7% | -73.8% | -80.8% | -79.8% |
| Market Cap | N/A | 24M | 10M | 15M | 25M | 25M |
| Avg. Price | N/A | 6.84 | 1.91 | 0.93 | 1.21 | 0.43 |
| Year-End Price | N/A | 3.52 | 0.88 | 1.01 | 1.13 | 0.43 |
FEMASYS INC passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 70.5%. Total shareholder yield (buybacks) is 0.2%.
FEMASYS INC (FEMY) has a 5-year average return on invested capital (ROIC) of -74.5%. This is below average and may indicate limited pricing power.
FEMASYS INC (FEMY) has a market capitalization of $25M. It is classified as a small-cap stock.
FEMASYS INC (FEMY) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.24%.
FEMASYS INC (FEMY) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
FEMASYS INC (FEMY) generated $-20 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
FEMASYS INC (FEMY) has a debt-to-equity ratio of 5.58. This indicates higher leverage, which may increase financial risk.
FEMASYS INC (FEMY) reported earnings per share (EPS) of $-0.85 in its most recent fiscal year.
FEMASYS INC (FEMY) has a return on equity (ROE) of -182.2%. A negative ROE may indicate losses or negative equity.
FEMASYS INC (FEMY) has a 5-year average gross margin of 70.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for FEMASYS INC (FEMY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
FEMASYS INC (FEMY) has a book value per share of $0.10, based on its most recent annual SEC filing.